A phase I evaluation of the effect of curcumin on dose‐limiting toxicity and pharmacokinetics of irinotecan in participants with solid tumors

• Main Authors: Olumide B. Gbolahan (Author), Bert H. O'Neil (Author), Autumn J. McRee (Author), Hanna K. Sanoff (Author), John K. Fallon (Author), Philip C. Smith (Author), Anastasia Ivanova (Author), Dominic T. Moore (Author), Julie Dumond (Author), Gary N. Asher (Author)
• Format: Book
• Published: Wiley, 2022-05-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Curcumin inhibits UDP‐glucuronyltransferases, a primary metabolic pathway for cancer chemotherapeutic agents like irinotecan. Concurrent administration of both agents may exacerbate irinotecan toxicity. We conducted this phase I study to determine the safety of concurrent curcumin and irino...